Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies

• Published in: International journal of hematology 2014-04, Vol.99 (4), p.477-486
• Main Authors: Hirabayashi, Kanae, Nakazawa, Yozo, Matsuura, Hiroki, Hara, Yosuke, Kurata, Takashi, Hirabayashi, Koichi, Saito, Shoji, Yoshikawa, Kentaro, Tanaka, Miyuki, Yanagisawa, Ryu, Sakashita, Kazuo, Koike, Kenichi
• Format: Article
• Language: English
• Subjects: Adipokines - blood; Adolescent; Biological and medical sciences; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - etiology; Diabetes Mellitus, Type 2 - metabolism; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Glucose - metabolism; Glucose Intolerance - diagnosis; Glucose Intolerance - etiology; Glucose Intolerance - metabolism; Hematologic and hematopoietic diseases; Hematologic Neoplasms - complications; Hematologic Neoplasms - therapy; Hematology; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Infant; Male; Medical sciences; Medicine; Medicine & Public Health; Oncology; Original Article; Prognosis; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-014-1536-8

Long-term surviving recipients of allogeneic hematopoietic stem cell transplantation (HSCT) often suffer from diabetes mellitus (DM). We sought to identify risk factors for the development of post-transplant DM and impaired glucose tolerance (IGT) in pediatric HSCT patients. Glucose tolerance statuses were evaluated in 22 patients aged 6.3–21.8 years who had received allogeneic HSCT between the ages of 0.8–13.5 years. Five patients were diagnosed as having type 2 DM, and treated with insulin or oral hypoglycemic agents. Five patients were included in the IGT group, and the remaining 12 children were in the normal glucose tolerance (NGT) group. The cumulative incidence of DM plus IGT was 11.6 % at 5 years and 69.3 % at 10 years. None of the patients were obese/overweight and none had a family history of DM. There were no significant differences in serum levels of leptin and adiponectin between the DM + IGT and the NGT groups. An average preprandial glucose levels in the DM + IGT group were significantly higher than those in the NGT group from preparative conditioning to 60 days after HSCT. In multivariate analysis, an age of ≥6 years at the time of HSCT was significantly associated with the development of DM + IGT. Additionally, careful follow-up is necessary, even for NGT patients.